Immuno-Oncology Resource Center
Immuno-Oncology Resource Center
February 10, 2020
1 min read
Save

FDA grants priority review to Kite’s CAR-T for mantle cell lymphoma

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

The FDA granted priority review to the investigational chimeric antigen receptor T-cell therapy KTE-X19 for the treatment of adults with relapsed or refractory mantle cell lymphoma.

KTE-X19 (Kite, Gilead) is an anti-CD19 autologous CAR T-cell therapy that targets the CD19 protein when it is expressed on the surface of cancer cells. Approval of KTE-X19 would make Kite the first manufacturer with more than one FDA-approved CAR T-cell therapy.

“Despite recent advances, patients with relapsed or refractory mantle cell lymphoma currently face a significant lack of effective treatment options once their disease no longer responds to currently available therapy,” Ken Takeshita, MD, global head of clinical development at Kite, said in a company-issued press release. “Based on the encouraging results for KTE-X19, we are eager to continue discussions with the FDA on how to bring this innovative treatment to these patients who may benefit from CAR T[-cell] therapy.”

The FDA accepted Kite’s biologics license application (BLA) for KTE-X19 for this indication in December, as Healio previously reported.

Kite supported the BLA with phase 2 data from the multicenter ZUMA-2 trial presented at last year’s ASH Annual Meeting and Exposition. The results showed an overall response rate of 93% and a complete response rate of 67%. Researchers observed grade 3 or higher cytokine release syndrome and neurotoxicity among 15% and 31% of patients, respectively. No patients experienced grade 5 cases of these toxicities.

The FDA set a target action date of Aug. 10.

KTE-X19 is being tested in clinical trials for additional indications that include adult acute lymphoblastic leukemia (ZUMA-3), pediatric ALL (ZUMA-4) and chronic lymphocytic leukemia (ZUMA-8).